{"id":66992,"date":"2026-06-01T20:15:51","date_gmt":"2026-06-01T12:15:51","guid":{"rendered":"https:\/\/flcube.com\/?p=66992"},"modified":"2026-06-01T20:15:52","modified_gmt":"2026-06-01T12:15:52","slug":"genfleets-gfs202a-becomes-worlds-first-cachexia-bispecific-antibody-to-show-clinical-activity-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66992","title":{"rendered":"GenFleet&#8217;s GFS202A Becomes World&#8217;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GenFleet Therapeutics (Shanghai) Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2595:HKG\">HKG: 2595<\/a>)<\/strong> presented <strong>preliminary Phase I clinical data<\/strong> for <strong>GFS202A<\/strong>, the <strong>world&#8217;s first bispecific antibody targeting cancer cachexia<\/strong>, at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong>. The <strong>GDF15\/IL-6 bispecific antibody (BsAb)<\/strong> demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with <strong>complete and sustained GDF15 inhibition<\/strong> achieved at the <strong>200 mg Q3W dose level<\/strong>. The data represents a breakthrough in addressing <strong>cancer cachexia<\/strong>, a devastating metabolic syndrome for which <strong>no targeted therapies have been approved<\/strong> by the FDA or NMPA.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GFS202A \u2013 GDF15\/IL-6 bispecific antibody<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cancer cachexia (first-in-class)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase I clinical trial<\/td><\/tr><tr><td><strong>Presentation Venue<\/strong><\/td><td>ASCO Annual Meeting 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>World&#8217;s first cachexia bispecific antibody in clinical development<\/td><\/tr><tr><td><strong>Regulatory Gap<\/strong><\/td><td>No approved targeted therapies for cachexia (FDA\/NMPA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-trial-results\" class=\"wp-block-heading\">Clinical Trial Results<\/h2>\n\n\n\n<h3 id=\"h-pharmacokinetics-amp-target-engagement\" class=\"wp-block-heading\">Pharmacokinetics &amp; Target Engagement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dose Response<\/strong>: GFS202A exposure increased with ascending doses without significant accumulation<\/li>\n\n\n\n<li><strong>Target Inhibition<\/strong>: <strong>Complete and sustained GDF15 inhibition<\/strong> observed from <strong>200 mg Q3W dose level<\/strong><\/li>\n\n\n\n<li><strong>Dual Pathway<\/strong>: Simultaneous targeting of <strong>GDF15 and IL-6<\/strong> pathways implicated in cachexia pathogenesis<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-activity\" class=\"wp-block-heading\">Clinical Activity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Body Weight<\/strong>: Improved <strong>tumor-associated body weight loss<\/strong> after six weeks of treatment<\/li>\n\n\n\n<li><strong>Muscle Mass<\/strong>: Reversal of <strong>muscle wasting<\/strong> in treated patients<\/li>\n\n\n\n<li><strong>Appetite<\/strong>: <strong>Most patients experienced improved appetite<\/strong> following treatment<\/li>\n\n\n\n<li><strong>Inflammation<\/strong>: Hematological testing showed <strong>alleviation of tumor-associated systemic inflammation<\/strong><\/li>\n\n\n\n<li><strong>Nutrition<\/strong>: Evidence of improved <strong>nutritional status<\/strong> and reduced depletion markers<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tolerability<\/strong>: <strong>Favorable overall safety and tolerability profile<\/strong><\/li>\n\n\n\n<li><strong>Adverse Events<\/strong>: No dose-limiting toxicities reported at therapeutic dose levels<\/li>\n\n\n\n<li><strong>Clinical Feasibility<\/strong>: Suitable for chronic administration in frail cancer patient populations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-unmet-need\" class=\"wp-block-heading\">Disease Context &amp; Unmet Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cancer cachexia<\/strong> represents one of oncology&#8217;s most challenging unmet needs:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Affects <strong>50\u201380% of advanced cancer patients<\/strong>, contributing to <strong>20\u201330% of cancer deaths<\/strong><\/li>\n\n\n\n<li><strong>Pathophysiology<\/strong>: Complex metabolic syndrome driven by multiple inflammatory cytokines including <strong>GDF15 and IL-6<\/strong><\/li>\n\n\n\n<li><strong>Current Management<\/strong>: Limited to nutritional support and appetite stimulants with minimal efficacy<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong>: Associated with <strong>reduced treatment tolerance, quality of life, and survival<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>dual-pathway inhibition strategy<\/strong> addresses the multifactorial nature of cachexia:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GDF15<\/strong>: Regulates appetite and energy expenditure through brainstem receptors<\/li>\n\n\n\n<li><strong>IL-6<\/strong>: Drives systemic inflammation and muscle protein breakdown<\/li>\n\n\n\n<li><strong>Synergistic Effect<\/strong>: Simultaneous blockade may provide superior efficacy compared to single-target approaches<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This Phase I data validates our hypothesis that dual inhibition of GDF15 and IL-6 can meaningfully impact cancer cachexia,&#8221; said Dr. Zhang Min, Chief Executive Officer of GenFleet Therapeutics. &#8220;As the world&#8217;s first bispecific antibody to enter clinical development for this devastating condition, GFS202A has the potential to transform care for millions of cancer patients suffering from cachexia-related complications.&#8221;<\/p>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The breakthrough positions GenFleet at the forefront of a completely untapped therapeutic area:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity<\/strong>: Global cachexia market projected to reach <strong>$3\u20135 billion annually<\/strong> if effective therapies emerge<\/li>\n\n\n\n<li><strong>First-Mover Advantage<\/strong>: No competing targeted therapies in late-stage development<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Potential for accelerated approval given high unmet need and lack of alternatives<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Applicable across multiple cancer types where cachexia is prevalent (pancreatic, gastric, lung, colorectal)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view GFS202A as a <strong>high-value asset<\/strong> with potential for <strong>peak annual sales of $1\u20132 billion<\/strong> if Phase II\/III trials confirm clinical benefit, given the substantial patient population and premium pricing potential for first-in-class cachexia therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for GFS202A. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100052_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060100052_c.\"><\/object><a id=\"wp-block-file--media-c33fdcf0-37e1-470d-8324-01f1f41c7b8a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100052_c.pdf\">2026060100052_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100052_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c33fdcf0-37e1-470d-8324-01f1f41c7b8a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,1682,4345,28],"class_list":["post-66992","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-genfleet-therapeutics","tag-hkg-2595","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenFleet&#039;s GFS202A Becomes World&#039;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the world&#039;s first bispecific antibody targeting cancer cachexia, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The GDF15\/IL-6 bispecific antibody (BsAb) demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with complete and sustained GDF15 inhibition achieved at the 200 mg Q3W dose level. The data represents a breakthrough in addressing cancer cachexia, a devastating metabolic syndrome for which no targeted therapies have been approved by the FDA or NMPA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66992\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet&#039;s GFS202A Becomes World&#039;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the world&#039;s first bispecific antibody targeting cancer cachexia, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The GDF15\/IL-6 bispecific antibody (BsAb) demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with complete and sustained GDF15 inhibition achieved at the 200 mg Q3W dose level. The data represents a breakthrough in addressing cancer cachexia, a devastating metabolic syndrome for which no targeted therapies have been approved by the FDA or NMPA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66992\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T12:15:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T12:15:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66992#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66992\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet&#8217;s GFS202A Becomes World&#8217;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026\",\"datePublished\":\"2026-06-01T12:15:51+00:00\",\"dateModified\":\"2026-06-01T12:15:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66992\"},\"wordCount\":598,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"GenFleet Therapeutics\",\"HKG: 2595\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66992#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66992\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66992\",\"name\":\"GenFleet's GFS202A Becomes World's First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T12:15:51+00:00\",\"dateModified\":\"2026-06-01T12:15:52+00:00\",\"description\":\"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the world's first bispecific antibody targeting cancer cachexia, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The GDF15\\\/IL-6 bispecific antibody (BsAb) demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with complete and sustained GDF15 inhibition achieved at the 200 mg Q3W dose level. The data represents a breakthrough in addressing cancer cachexia, a devastating metabolic syndrome for which no targeted therapies have been approved by the FDA or NMPA.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66992#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66992\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66992#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet&#8217;s GFS202A Becomes World&#8217;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet's GFS202A Becomes World's First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the world's first bispecific antibody targeting cancer cachexia, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The GDF15\/IL-6 bispecific antibody (BsAb) demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with complete and sustained GDF15 inhibition achieved at the 200 mg Q3W dose level. The data represents a breakthrough in addressing cancer cachexia, a devastating metabolic syndrome for which no targeted therapies have been approved by the FDA or NMPA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66992","og_locale":"en_US","og_type":"article","og_title":"GenFleet's GFS202A Becomes World's First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026","og_description":"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the world's first bispecific antibody targeting cancer cachexia, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The GDF15\/IL-6 bispecific antibody (BsAb) demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with complete and sustained GDF15 inhibition achieved at the 200 mg Q3W dose level. The data represents a breakthrough in addressing cancer cachexia, a devastating metabolic syndrome for which no targeted therapies have been approved by the FDA or NMPA.","og_url":"https:\/\/flcube.com\/?p=66992","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T12:15:51+00:00","article_modified_time":"2026-06-01T12:15:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66992#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66992"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet&#8217;s GFS202A Becomes World&#8217;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026","datePublished":"2026-06-01T12:15:51+00:00","dateModified":"2026-06-01T12:15:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66992"},"wordCount":598,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Clinical trial results","GenFleet Therapeutics","HKG: 2595","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66992#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66992","url":"https:\/\/flcube.com\/?p=66992","name":"GenFleet's GFS202A Becomes World's First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T12:15:51+00:00","dateModified":"2026-06-01T12:15:52+00:00","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the world's first bispecific antibody targeting cancer cachexia, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The GDF15\/IL-6 bispecific antibody (BsAb) demonstrated promising clinical activity in reversing tumor-associated body weight loss and muscle wasting, with complete and sustained GDF15 inhibition achieved at the 200 mg Q3W dose level. The data represents a breakthrough in addressing cancer cachexia, a devastating metabolic syndrome for which no targeted therapies have been approved by the FDA or NMPA.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66992#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66992"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66992#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet&#8217;s GFS202A Becomes World&#8217;s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66992"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66992\/revisions"}],"predecessor-version":[{"id":66994,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66992\/revisions\/66994"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}